Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML3060

Sigma-Aldrich

Panobinostat

≥98% (HPLC)

Synonym(s):

(2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide, LBH 589, LBH-589, LBH589, N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, NVP-LBH589

Sign Into View Organizational & Contract Pricing

Select a Size

10 MG
£81.40
50 MG
£313.00

£81.40

Please contact Customer Service for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
10 MG
£81.40
50 MG
£313.00

About This Item

Empirical Formula (Hill Notation):
C21H23N3O2
CAS Number:
404950-80-7
Molecular Weight:
349.43
MDL number:
MFCD09833242
UNSPSC Code:
12352200
NACRES:
NA.77

£81.40

Please contact Customer Service for Availability
Request a Bulk Order

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC1=C(CCNCC2=CC=C(/C=C/C(NO)=O)C=C2)C3=CC=CC=C3N1

InChI

1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+

InChI key

FPOHNWQLNRZRFC-ZHACJKMWSA-N

Biochem/physiol Actions

Orally active, potent, cinnamoyl hydroxamate-type pan-histone deacetylase inhibitor with anti-cancer efficacy in vitro and in vivo.
Panobinostat (LBH589) is an orally active, potent, cinnamoyl hydroxamate-type pan-histone deacetylase inhibitor (class I HDAC1/2/3/8 IC50 = 2.5/13.2/2.1/277 nM; IIA HDAC4/5/7/9 IC50 = 203/7.8/531/5.7 nM; IIB HDAC6/10 IC50 = 10.5/2.3 nM, IV HDAC11 IC50 = 2.7 nM) with anti-cancer efficacy in vitro and in vivo.

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Inhalation

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000366703
0000366703
0000182918

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kenji Fujimoto et al.
Neuro-oncology advances, 2(1), vdaa084-vdaa084 (2020-08-15)
Polyglutamylation is a reversible protein modification that commonly occurs in tumor cells. Methotrexate (MTX) in tumor cells is polyglutamylated and strongly binds to dihydrofolate reductase (DHFR) without competitive inhibition by leucovorin. Therefore, tumor cells with high polyglutamylation levels are supposed
Chie Ishikawa et al.
European journal of haematology, 105(6), 763-772 (2020-08-12)
New effective therapeutic strategies for human T-cell leukemia virus type 1 (HTLV-1)-driven adult T-cell leukemia (ATL) are required because of resistance to chemotherapeutic agents. Here, we aimed to determine the therapeutic efficacy of a dual phosphoinositide 3 kinase (PI3K)/histone deacetylase
David I Sandberg et al.
Journal of neurosurgery. Pediatrics, 1-9 (2020-05-02)
Chemotherapy infusions directly into the fourth ventricle may play a role in treating malignant fourth-ventricular tumors. This study tested the safety and pharmacokinetics of short-term and long-term administration of MTX110 (soluble panobinostat; Midatech Pharma) into the fourth ventricle of nonhuman
Shan Su et al.
Frontiers in microbiology, 11, 1584-1584 (2020-08-09)
Invasive fungal infections are an emerging problem worldwide, which bring huge health challenges. Candida albicans, the most common opportunistic fungal pathogen, can cause bloodstream infections with high mortality in susceptible hosts. At present, available antifungal agents used in clinical practice
Yang Zhang et al.
Frontiers in cell and developmental biology, 8, 652-652 (2020-08-15)
We investigated the therapeutic potential of targeting integrin/FAK-dependent signaling, an adhesion receptor-mediated pathway that has been increasingly linked to non-small cell lung cancer (NSCLC) malignancy. Our analysis of the TCGA cohort showed that a subset of pro-tumorigenic integrins, including α1β1
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service